Advertisement

Journal of Neuroinflammation

, 13:237 | Cite as

Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway

  • Lauren J. Simmons
  • Monique  C. Surles-Zeigler
  • Yonggang Li
  • Gregory D. Ford
  • Gale D. Newman
  • Byron D. Ford
Open Access
Research

Abstract

Background

We previously demonstrated that neuregulin-1 (NRG-1) was neuroprotective in rats following ischemic stroke. Neuroprotection by NRG-1 was associated with the suppression of pro-inflammatory gene expression in brain tissues. Over-activation of brain microglia can induce pro-inflammatory gene expression by activation of transcriptional regulators following stroke. Here, we examined how NRG-1 transcriptionally regulates inflammatory gene expression by computational bioinformatics and in vitro using microglial cells.

Methods

To identify transcriptional regulators involved in ischemia-induced inflammatory gene expression, rats were sacrificed 24 h after middle cerebral artery occlusion (MCAO) and NRG-1 treatment. Gene expression profiles of brain tissues following ischemia and NRG-1 treatment were examined by microarray technology. The Conserved Transcription Factor-Binding Site Finder (CONFAC) bioinformatics software package was used to predict transcription factors associated with inflammatory genes induced following stroke and suppressed by NRG-1 treatment. NF-kappa B (NF-kB) was identified as a potential transcriptional regulator of NRG-1-suppressed genes following ischemia. The involvement of specific NF-kB subunits in NRG-1-mediated inflammatory responses was examined using N9 microglial cells pre-treated with NRG-1 (100 ng/ml) followed by lipopolysaccharide (LPS; 10 μg/ml) stimulation. The effects of NRG-1 on cytokine production were investigated using Luminex technology. The levels of the p65, p52, and RelB subunits of NF-kB and IkB-α were determined by western blot analysis and ELISA. Phosphorylation of IkB-α was investigated by ELISA.

Results

CONFAC identified 12 statistically over-represented transcription factor-binding sites (TFBS) in our dataset, including NF-kBP65. Using N9 microglial cells, we observed that NRG-1 significantly inhibited LPS-induced TNFα and IL-6 release. LPS increased the phosphorylation and degradation of IkB-α which was blocked by NRG-1. NRG-1 also prevented the nuclear translocation of the NF-kB p65 subunit following LPS administration. However, NRG-1 increased production of the neuroprotective cytokine granulocyte colony-stimulating factor (G-CSF) and the nuclear translocation of the NF-kB p52 subunit, which is associated with the induction of anti-apoptotic and suppression of pro-inflammatory gene expression.

Conclusions

Neuroprotective and anti-inflammatory effects of NRG-1 are associated with the differential regulation of NF-kB signaling pathways in microglia. Taken together, these findings suggest that NRG-1 may be a potential therapeutic treatment for treating stroke and other neuroinflammatory disorders.

Keywords

Bioinformatics Gene expression Inflammation Ischemia Microarray Neuregulin Stroke Transcription factor-binding site (TFBS) 

Abbreviations

BSA

Bovine serum albumin

CONFAC

Conserved Transcription Factor-Binding Site Finder

DMEM

Dulbecco’s modified Eagle’s media

ECA

External carotid artery

ELISA

Enzyme-linked immunosorbent assay

FBS

Fetal bovine serum

ICA

Internal carotid artery

IL-1β

Interleukin-1β

IkB

Inhibitory kappa B

IKK

IkB kinase

IPA

Ingenuity Pathway Analysis

LPS

Lipopolysaccharide

MCA

Middle cerebral artery

MCAO

Middle cerebral artery occlusion

NF-kB

Nuclear factor kappa B

NIK

NF-kB-inducing kinase

NO

Nitric oxide

NRG-1

Neuregulin-1

PBS

Phosphate-buffered saline

PVDF

Polyvinylidene difluoride membranes

ROS

Reactive oxygen species

SDS-PAGE

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

TFBS

Transcription factor-binding sites

TNF-α

Tumor necrosis factor α

TTC

Triphenyltetrazolium chloride

Background

The actions of neuregulins have been demonstrated in normal brain function and in neuroprotection following cerebral ischemia. Studies from our laboratory and others demonstrated that neuregulin-1 (NRG-1) reduced ischemia-induced neuronal death in rodent models of focal stroke [1, 2, 3]. NRG-1 was neuroprotective with a therapeutic window of >13 h and significantly improved neurological function [2, 4]. Neuroprotection by NRG-1 was also associated with the inhibition of pro-inflammatory gene expression following ischemia [2, 3, 5, 6, 7, 8]. The anti-inflammatory effects of NRG-1 have also been shown in other animal models of neuroinflammation including cerebral malaria and nerve agent intoxication [9, 10] and in vivo using cultured macrophages and microglia [3, 11]. However, the cellular and molecular mechanisms involved in the immunomodulatory effects of NRG-1 remain unclear.

Neuronal death following ischemic stroke involves the induction of genes associated with a number of cellular functions, including apoptosis, inflammation, and oxidative stress [12, 13]. The initial inflammatory response following brain injury is mediated by the activation of its resident inflammatory cells, the microglia [14, 15, 16]. Activated microglia release inflammatory mediators such as reactive oxygen species (ROS), nitric oxide (NO), tumor necrosis factor α (TNF-α), and interleukin-1β (IL-1β) [17, 18, 19]. While the initial activation of microglia is the brain’s attempt to protect neurons, the over-activation of microglia leads to uncontrolled inflammation which exacerbates neuronal death [18, 20, 21]. Nuclear factor kappa B (NF-kB) is a transcription factor widely known to be associated with inflammatory responses following ischemia and other neuroinflammatory disorders [22, 23, 24]. There are five members of the NF-kB family which include p65 (RelA), RelB, c-Rel, p50/105 (NF-kB1), and p52/p100 (NF-kB2), which exist in unstimulated cells as homo or heterodimers bound to inhibitory kB (IkB) family proteins. Activation of the canonical NF-kB pathway triggers IkB kinase (IKK) activity, leading to phosphorylation and degradation of IkB proteins and the release of NF-kB p65/p50 heterodimers. The released p65/p50 NF-kB dimers translocate from the cytoplasm to the nucleus where they bind to specific DNA sequences and promote transcription of target genes [23, 24]. In the canonical pathway, NF-kB activation triggers the production of pro-inflammatory cytokines and NO [18, 25, 26]. Studies have shown that inhibition of the canonical NF-kB pathway prevents the production of pro-inflammatory cytokines [27, 28, 29]. The activation of the NF-kB alternative/non-canonical pathway involves NF-kB-inducing kinase (NIK), a member of the MAP kinase family, which activates IKKα, resulting in the translocation of RelB/p52 NF-kB heterodimers to the nucleus [30, 31, 32, 33, 34]. The alternative NF-kB pathway has been shown to stimulate the production of anti-apoptotic and anti-inflammatory molecules [31, 35, 36, 37, 38, 39]. The effects of NRG-1 have been shown to be mediated by NF-kB signaling during tumorigenesis in cancers and axonal myelination [40, 41, 42, 43, 44, 45]. Specifically, NRG-1 has been shown to activate NIK through its association with the NRG-1’s erbB receptors [46].

To identify transcriptional regulators involved in ischemia-induced inflammatory gene expression, we examined gene expression profiles of brain tissues following ischemia and NRG-1 treatment. Using Conserved Transcription Factor-Binding Site Finder (CONFAC) software, we performed computational analysis to predict transcriptional regulators of genes that were induced following ischemic stroke but were downregulated by NRG-1. CONFAC identifies conserved transcription factor-binding sites significantly over-represented in promoter regions of a set of genes of interest compared to random control set of genes [47]. NF-kB was identified as one of the top potential regulators of NRG-1-suppressed genes following ischemia. Using N9 microglial cells, we observed that NRG-1 blocked the phosphorylation and degradation of IkB-α, leading to the attenuation of classical NF-kB activation. NRG-1 increased the nuclear translocation of the p52 subunit of NF-kB and the levels of anti-apoptotic cytokines G-CSF and IL-9, suggesting a role for the alternative NF-kB pathway. Understanding these mechanisms will provide insight into the molecular processes behind the neuroprotective and anti-inflammatory abilities of NRG-1.

Methods

Transient middle cerebral artery occlusion (MCAO)

All animals were treated humanely and with regard for alleviation of suffering and pain. All surgical protocols involving animals were performed by sterile/aseptic techniques and were approved by the Institutional Animal Care and Use Committee at Morehouse School of Medicine prior to the initiation of experimentation. Adult male Sprague-Dawley rats (250–300 g; Charles River Laboratory International, Inc., USA) were housed in standard cages in a temperature-controlled room (22 ± 2 °C) on a 12-h reverse light-dark cycle. Food and water were provided ad libitum.

Animals were randomly allocated into three groups: sham (control), middle cerebral artery occlusion (MCAO) + vehicle treatment (MCAO) and MCAO + NRG-1 (MCAO + NRG1). Rats were anesthetized with a ketamine/xylazine solution (100/10 mg/kg, i.p.) prior to surgery. After anesthesia administration, a rectal probe monitored the core body temperature and a Homoeothermic Blanket Control Unit (Harvard Apparatus, Hollister, MA) was used to ensure the body temperature maintained at 37 °C. Cerebral blood flow was monitored throughout the length of the surgery by a continuous laser Doppler flowmeter (Perimed, Ardmore, PA), with a laser Doppler probe placed 7 mm lateral and 2 mm posterior to bregma in a thinned cranial skull window.

Rats in the treatment groups (MCAO and MCAO + NRG1) were subjected to a left transient MCAO. MCAO was induced by the intraluminal suture method as previously described [3]. Briefly, a 4-cm length 4-0 surgical monofilament nylon suture coated with silicon (Doccol Corp., Sharon, MA) was inserted from the external carotid artery (ECA) into the internal carotid artery (ICA) and then into the Circle of Willis, to occlude the origin of the left middle cerebral artery (MCA). After 1.5 h of ischemia, the nylon suture was removed and the ischemic brain was reperfused for 22.5 h before sacrifice. Rats in the sham control group underwent the same procedure as those in the treatment groups, but a filament was not inserted into the ICA. Animals were randomly assigned into treatment groups and either administered 50 μl of NRG-1β reconstituted with 1 % bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (MCAO + NRG1; 20 μg/kg; EGF-like domain, R&D Systems, Minneapolis, MN) or vehicle (MCAO; 1 % BSA in PBS) All treatments were administered by bolus injection into the ICA through ECA immediately before MCAO. Animals were sacrificed 24 h after MCAO. All NRG-1 and vehicle treatment studies were performed in a blinded manner.

RNA preparation and microarray analysis

Microarray analysis was performed as we previously described [3, 48, 49]. Animals were sacrificed, and their brains removed 24 h following MCAO. Removed brains were sliced into 2-mm coronal sections (approximately +3.0 to −5.0 from bregma) using a brain matrix. Tissue from the ipsilateral tissue from the two middle slices (+1 to −3 from bregma) of MCAO treated (n = 3) and MCAO + NRG1 treated (n = 3) and sham animals (n = 3) were used for RNA isolation, while the two outer slices of tissue were used for staining with 2,3,5-triphenyltetrazolium chloride (TTC), in order to confirm infarct formation. Total RNA extraction was performed using TRIzol Reagent (Life Technologies, Rockville, MD, USA), cleaned (RNAqueous Kit Ambion, Austin, TX, USA), and converted to double-stranded complementary DNA (cDNA) (Invitrogen, Superscript Choice System, Carlsbad, CA, USA) using T7-(dT)24 primer. Cleanup of double-stranded cDNA used Phase Lock Gels (Eppendorf, Westbury, NY, USA)-Phenol/Chloroform/Isoamyl Alcohol (Sigma, St. Louis, MO, USA). cRNA was synthesized using a RNA transcript labeling kit (Enzo Diagnostics, Farmingdale, NY, USA). Biotin-labeled cRNA was cleaned up using a GeneChip Sample Cleanup Module (Affymetrix Inc., Santa Clara, CA, USA) and quantified using a spectrophotometer. Twenty micrograms of the in vitro transcription product was fragmented by placing at 94 °C for 35 min in fragmentation buffer. Following fragmentation, 15 μg of the biotinylated cRNA was hybridized to an Affymetrix Rat Genome U34A GeneChip. The chips were hybridized at 45 °C for 16 h, and then washed, stained with streptavidin-phycoerythrin, and scanned according to the manufacturing guidelines.

Microarray data analysis

Affymetrix Expression Console software (Affymetrix, Santa Clara, CA) was used for initial data processing. Affymetrix microarrays contain the hybridization, labeling, and housekeeping controls that help determine the success of the hybridizations. The Affymetrix Expression Analysis algorithm uses the Tukey’s biweight estimator to provide a robust mean signal value and the Wilcoxon’s rank test to calculate a significance or p value and detection call for each probe set. The detection p value is calculated using a discrimination score (R) for all probes. The discrimination score is a basic property of a probe pair that describes its ability to detect its intended target. It measures the target-specific intensity differences of the probe pair (perfect match (PM)–mismatch (MM)) relative to its overall hybridization intensity (PM + MM). Background estimation is provided by a weighted average of the lowest 2 % of the feature intensities. Mismatch probes are utilized to adjust the PM intensity. Linear scaling of the feature level intensity values, using the trimmed mean, is the default to make the means equal for all arrays being analyzed. False-negative and false-positive rates are minimized by subtracting nonspecific signal from the PM probe intensities and performing an intensity-dependent normalization at the probe set level. Calculation of fold change and the presence of genes in the tissue were analyzed in Microsoft Excel. Changes in gene expression were compared between the control (sham) and following MCAO and MCAO + NRG-1 treatment. Gene expression values that increased or decreased by twofold or more were statistically significant (p < 0.05) using two-way ANOVA. The list of genes upregulated twofold or more by ischemia and decreased 50 % or more by NRG-1 was analyzed using Ingenuity Pathway Analysis (IPA) software (Qiagen, Redwood City, CA; www.ingenuity.com) overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. Fischer’ s exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that network is due to chance alone. The functions, canonical pathways, and gene networks that were most significant to the dataset were identified. IPA identified 64 inflammatory genes that were upregulated twofold or more by MCAO and reduced 50 % or more by NRG-1.

CONFAC analysis

Using CONFAC software, we further examined the IPA-identified inflammatory genes [47, 48]. A tab-delimited text file containing the gene name and RefSEQ ID of the clusters of interest (genes) was uploaded to the CONFAC web browser interface (http://confac.emory.edu/). CONFAC software identified mouse orthologs from the uploaded gene list (from UCSC and ENSEMBL genomes). CONFAC software next identified significantly conserved sequences (e value <0.001), which were analyzed for transcription factor-binding sites (TFBS) using MATCH™ software. The final output table consisted of the cohort list of genes (column) and the position weight matrix (collected in TRANSFAC® database) identified potential TFBS and the number of TFBS determined for each gene of interest. The CONFAC program then allowed for additional analysis using the Mann-Whitney U test, which facilitated the statistical analysis of TFBS over-represented in the sample dataset compared to the seven control random control datasets provided by CONFAC.

N9 microglial cell culture

The murine N9 microglial cell line was kindly provided by Dr. Celine Beamer (Department of Biomedical and Pharmaceutical Sciences, University Montana). N9 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) with 4 mM l-glutamine, supplemented with 10 % fetal bovine serum (FBS), streptomycin (100 U/ml), and penicillin (100 U/ml). The cells were maintained in 95 % air and 5 % CO2-humified atmosphere at 37 °C and were passaged every 3 days. For culturing with various stimulants, N9 cells were plated into 12-well plates in prepared culture medium and NRG-1 and lipopolysaccharide (LPS) were applied at the following final concentrations: LPS (10 μg/ml) and NRG-1 (100 ng/ml in 1 % BSA/PBS; recombinant human neuregulin1-beta1 EGF-like domain, R&D Systems). N9 cells were either pre-treated with NRG-1 (100 ng/ml) for 24 h followed by stimulation with LPS (10 μg/ml) or treated with LPS or NRG-1 alone for the indicated times (1–24 h).

Luminex multiplex enzyme-linked immunosorbent assay (ELISA)

Cell lysates were taken at 1, 3, 6, and 24 h time points following LPS treatment. The cytokine release was measured in cell culture supernatants by Luminex technology using the manufacturer’s protocol (Bio-Rad, Hercules, CA). Data analysis was performed using Bio-Plex Manager software on the Bio-Plex 200 system. Experiments were performed four times in duplicate wells.

Protein isolation and western blot

Proteins were isolated using whole cell extraction reagent M-PER (Pierce Biotechnology, Rockford, IL) or NE-PER Nuclear and Cytoplasmic Extraction Reagent (Thermo Scientific) according to the manufacturer’s instructions. Protein concentrations were determined by Bradford protein assay (Bio-Rad). Fifty micrograms of protein lysate was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (PVDF) (Bio-Rad, CA). The membranes were blocked with 3 % nonfat dry milk in 0.1 % Tween-20/Tris-buffered saline for 1 h at room temperature and subsequently incubated with the primary antibodies overnight, followed by incubation in corresponding secondary horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Blots were developed using immuno-western star ECL detection kits (Bio-Rad). The optical densities of the antibody-specific bands were analyzed by a Luminescent Image Analyzer, LAS-4000 (Fuji, Japan). The following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used: NF-kB p65 (sc-372; 1:200), IkB-α (sc-371; 1:200), YY1 (sc-281; 1:200), and β-actin (sc-130656; 1:200).

IkB-α (total/phospho) InstantOne ELISA

The phosphorylation of IkB-α was determined using an enzyme-linked immunosorbent assay (ELISA)-based assay kit according to the manufacturer’s protocol (Affymetrix eBioscience, San Diego, CA). To analyze the results, we calculated the average values for each treatment group. This assay was run four times in duplicate.

Active motif transAM NF-kB family ELISA

Nuclear extracts were isolated using NE-PER Nuclear and Cytoplasmic Extraction kit according to the manufacturer’s protocol (Thermo Scientific, Waltham, MA). ELISA was performed using the manufacturer’s protocol. To analyze the results, the optical density was read using 450 nm with an optional reference wavelength of 655 nm. This assay was run three times in duplicate.

Statistical analysis

Statistical analysis for ELISAs and western blot data was performed by ANOVA with Tukey’s post hoc test for multiple comparisons where indicated. Significance was determined using a p value less than 0.05.

Results

CONFAC analysis predicts transcription factor NF-kB to be regulated following MCAO + NRG1

NRG-1 has been shown to prevent neuronal injury when administered before or after MCAO. In these studies, rats were treated with NRG-1 immediately prior to transient MCAO for maximal effect. In representative TTC-stained coronal brain sections, rats were administered vehicle (Fig. 1a) or NRG-1 before MCAO (Fig. 1b). The white area indicates damaged neuronal cells (arrows) and red staining indicates normally functioning cells. RNA was isolated from the ipsilateral hemisphere of each experimental group (sham controls, MCAO, and MCAO + NRG1) and used to examine gene expression profiles in brain tissues from each condition. Using microarray and IPA analysis, we found that 64 inflammatory genes were increased twofold or more 24 h following MCAO and reduced by 50 % with NRG-1 treatment (Table 1). The list included a number of well-characterized pro-inflammatory molecules, including IL-1β, PTGS2/COX2 (protaglandin-endoperoxide synthase-2/cyclooxygenase-2), CD36, SPP1 (secreted phosphoprotein 1/osteopontin), and S100 calcium-binding proteins. IL-1β and PTGS2/COX2 induction by MCAO and in a monocytic cell line, respectively, and attenuation by NRG-1 were previously validated by qPCR [3]. CONFAC analysis software recognized 54 genes in our dataset and analyzed TFBS in the promoters of those genes. CONFAC identified 12 TFBS as over-represented in our dataset compared to the random control datasets. The TFBS included MAZ, NFKAPPAB65, XBP1, XFD1, SOX, ATF3, NFE2, IRF7, GABP, EBF, and CACCBINDINGFACTOR (Fig. 2). NFKAPPAB65 (NF-kB p65 subunit) has been previously associated with stroke and the effects of NRG-1 in breast cancer and neuronal myelination [40, 41, 42, 43, 45], so we further investigated the role of NF-kB in NRG-1-mediated neuroinflammation.
Fig. 1

Neuregulin-1 administration reduces MCAO/reperfusion-induced brain infarction. Representative TTC-stained coronal brain sections are shown. Rats were administered vehicle (a) or NRG-1 before MCAO (b). The white area indicates damaged neuronal cells (arrows) and red staining indicates normally functioning cells

Table 1

Inflammatory genes induced by ischemia and downregulated by NRG-1

A kinase anchor protein 12

Akap12

Actin-related protein 2/3 complex subunit 1B

Arpc1b

Activating transcription factor 3

Atf3

Annexin A1

Anxa1

Annexin A2

Anxa2

Benzodiazepine receptor (peripheral)-associated protein 1

bzrp

Brain-derived factor

Bdnf

CAMP responsive element modulator

Crem

Cartilage oligomeric matrix protein

Comp

Catechol-O-methyltransferase

Comt

CCAAT/enhancer-binding protein, delta

Cebpd

CD36 antigen

cd36

Cellular retinoic-binding protein 2

Crabp2

Crystallin, alpha B

Cryab

Cytochrome P450 family 1

Cyp1b1

Deiodinase iodothyronine type III

Dio3

Dyskeratosis congenita 1

Dkc1

Early growth response 1

Egr1

Endothelin converting enzyme 1

Ece1

Fx receptor, IgG, low-affinity III

Fcgr3

Galanin

Gal

Glycosylation-dependent cell adhesion molecule 1

Glycam1

Guanine nucleotide-binding protein gamma 11

Gng11

Guanylate-binding protein

Gbp2

Heat shock protein 4

Hspa4

High mobility group of box 2

Hmgb2

Homer scaffolding protein 1

Homer1

Inhibitor of DNA binding 1

Id1

Insulin-like growth factor-binding protein 3

Igfbp3

Interleukin 1 beta

IL1b

Isopentenyl-diphosphate delta isomerase 1

Idi1

Kininogen 1

Kng

Kruppel-like factor 4

Klf4

Lectin galatoside-binding soluble 2

LgalS2

Lipocalin 2

Lcn

Lipopolysaccharide-binding protein

Lbp

Lysozyme

Lyz

Matrix gla protein

Mgp

Matrix metallopeptidase 9

MMP9

Mitogen-activated protein kinase e, E3

Map

Oxidized low-density lipoprotein receptor 1

Olr1

Phospholipase A1

Pspla1

Phosphoribosyl pyrophosphate synthase-associated protein 1

Prpsap1

Phosphorylase glycogen liver

Pygl

Plasminogen activator tissue

Plat

Potassium channel member 12

Kcnj12

Potassium channel, two pore domain subfamily K member 3

Kcnk3

Protaglandin-endoperoxide synthase 2

Ptgs2

Rentinol-binding protein 1

Rbp1

Ret proto-oncogene

Ret

Ribosomal protein S15

Rps15

S100 calcium-binding protein A10

S100a10

S100 calcium-binding protein A4

S100a4

S100 calcium-binding protein A8

S100a8

S100 calcium-binding protein A9

S100a9

Secreted phosphoprotein 1

Spp1

Serpin peptidase inhibitor

Serpin1

Syndecan 1

Sdc1

Thyrotropin releasing hormone

Trh

TIMP metallopeptidase inhibitor 1

Timp1

Transgelin

Tagln

V-ETS avian erythroblastosis virus E26 oncogene homolog 1

ETS1

VGF nerve growth factor inducible

Vgf

Vimentin

Vim

Fig. 2

Predicted transcription factor-binding site (TFBS) activity for gene promoters using CONFAC analysis. CONFAC compared our gene list to seven random control datasets to identify statistically over-represented TFBS in genes altered by stroke and reversed by NRG-1. CONFAC identified 12 TFBS that were statistically over-represented. Blue bars represent the average number of TFBS/promoter for each transcription factor in our data set. Red bars are the average number of TFBS/promoter for each transcription factor in the control datasets. p < 0.05 for all transcription factors in the graph

NRG-1 suppressed the release of cytokines TNF-α and IL-6 in LPS-stimulated N9 microglial cells

We previously demonstrated the induction of IL-1β and monocyte chemoattractant protein 1 (MCP-1/CCL2) following MCAO and their inhibition by NRG-1 [3]. To determine whether NRG-1 inhibits the general production and release of pro-inflammatory cytokines, N9 microglia were pre-treated with NRG-1 followed by stimulation with LPS. Cytokine levels in the conditioned medium were measured by Luminex multiplex ELISA. Following LPS stimulation, there was an increase in TNF-α production and release at 3, 6, and 24 h from microglial cells. NRG-1 pre-treatment significantly reduced the levels of TNF-α at 3 h (p = 0.0003), 6 h (p = 0.0011), and 24 h (p = 0.01) post-stimulation with LPS (Fig. 3a). LPS stimulation also increased IL-6, which was significantly reduced by NRG-1 at 6 h (p = 0.02) post-LPS stimulation (Fig. 3b).
Fig. 3

NRG-1 suppresses TNF-α and IL-6 concentrations in LPS-stimulated N9 microglia cells. N9 microglia cells were pre-treated with NRG-1 (100 ng/ml) for 24 h with or without LPS stimulation (10 μg/ml) for the indicated time points. Supernatants were collected, and TNF-α (a) and IL-6 (b) levels were determined by Luminex. Results are expressed as the mean +/− SD. Asterisk denotes a significant difference compared to cells treated with only LPS (p < 0.05)

NRG-1 attenuated LPS-stimulated phosphorylation and degradation of IkB-α in N9 microglial cells

In the canonical NF-kB pathway, IkB kinase (IKK) phosphorylates IkB-α triggering its ubiquitination and degradation. This allows the NF-kB p56 and p50 subunits to translocate to the nucleus, resulting in the production and secretion pro-inflammatory cytokines and chemokines. Here, we examined whether NRG-1 regulates LPS-stimulated IkB-α phosphorylation in N9 microglia cells. N9 cells were either pre-treated with NRG-1 for 24 h followed by stimulation with LPS or treated with LPS or NRG-1 alone for the indicated times (1–24 h). Using an ELISA system, phosphorylation of IkB-α in microglial cell lysates increased 1 h post-LPS stimulation, peaked at 3 h, and then returned to baseline 6–24 h following LPS stimulation (Fig. 4a, b). Pre-treatment with NRG-1 significantly reduced the phosphorylation of IkB-α in response to LPS stimulation at both the 1- and 3-h time points. We used western blot analyses to determine the effect of NRG-1 on the degradation of IkB-α. N9 cells were pre-treated with NRG-1 for 24 h followed by stimulation with LPS or treated with LPS or NRG-1 alone for 1 and 3 h. At the l-h time point, there was a reduction in IkB-α in LPS-treated cells when compared to controls; however, this was reversed in cells pre-treated with NRG-1 followed by LPS treatment (p = 0.008) (Fig. 5).
Fig. 4

NRG-1 suppresses the phosphorylation of IkB-α in LPS-stimulated N9 microglia cells. N9 microglial cells were pre-treated with 100 ng/ml NRG-1 for 24 h followed by the absence or presence of LPS (10 μg/ml) for indicated time points. a, b Cell lysates were taken and were assayed using ELISA. Results were expressed as the mean +/− SD. Asterisk denotes significant difference compared to cells treated with only LPS (p < 0.05)

Fig. 5

NRG-1 inhibits the degradation of IkB-α in LPS-stimulated N9 microglia cells. N9 microglial cells were pre-treated with 100 ng/ml NRG-1 for 24 h followed by the absence or presence of LPS (10 μg/ml) for 1 h (a) and 3 h (b). Whole cell extracts were taken from untreated cells or cells pre-treated NRG-1 alone or the absence or presence of LPS (10 μg/ml) and were assayed using western blot. The band intensity was quantified using studio lite imager and is presented relative to the level of β-actin. Data are presented for three independent experiments. Results were expressed as the mean +/− SD. Asterisk denotes significant difference compared to cells treated with only LPS (p < 0.05)

NRG-1 attenuated P65 nuclear translocation in N9 microglia cells

To determine if NRG-1 had an effect on the canonical NF-kB pathway, we used nuclear extracts for ELISA and western blot to examine the translocation of the NF-kB p65 subunit identified by CONFAC. We observed an increase in nuclear translocation of p65 in N9 cells treated with LPS alone. However, LPS-induced p65 translocation was significantly reduced in cells pre-treated with NRG-1 followed by LPS using ELISA (Fig. 6a; p = 0.004) and western blot (Fig. 6b, p = 0.003).
Fig. 6

NRG-1 reduces nuclear translocation of P65. N9 microglial cells were pre-treated with 100 ng/ml NRG-1 for 24 h followed by the absence or presence of LPS (10 μg/ml) for 3 h. Nuclear (a) and cytoplasmic (b) extracts were assayed using western blot. Nuclear extracts were assayed using ELISA (c). Data are presented from three independent experiments. Results were expressed as the mean +/− SD. Asterisk denotes significant difference compared to cells treated with only LPS (p < 0.05)

NRG-1 increased the nuclear translocation of the P52 subunit

It has been previously shown that NRG-1 is able to activate NF-kB-inducing kinase (NIK) which is a mediator of the alternative NF-kB pathway [46]. Here, we investigated if NRG-1 could affect LPS-mediated nuclear translocation of the p52 and RelB NF-kB subunits. LPS stimulation resulted in a decrease in nuclear p52 at 3 and 24 h post-treatment (Fig. 7a). NRG-1 pre-treatment significantly increased nuclear p52 levels at 3, 6, and 24 h post-LPS stimulation. Neither LPS nor NRG treatment altered nuclear levels of RelB in these studies (Fig. 7b).
Fig. 7

NRG-1 increased nuclear translocation of P52. N9 microglial cells were pre-treated with 100 ng/ml NRG-1 for 24 h followed by the absence or presence of LPS (10 μg/ml) for 3–24 h. Cell lysates were taken and were assayed using ELISA measuring levels of p52 (a) and RelB (b). Results were expressed as the mean +/− SD. Asterisk denotes significant difference compared to cells treated with only LPS (p < 0.05)

NRG-1 increased anti-apoptotic cytokines G-CSF and IL-9

Granulocyte colony-stimulating factor (G-CSF) is a target of NF-kB and has been shown to be neuroprotective in stroke by inducing anti-apoptotic pathways [50, 51, 52, 53]. The NF-kB inducible cytokine IL-9 has also been reported to prevent apoptosis. LPS stimulation of microglial cells did not affect G-CSF levels in medium. However, NRG-1 increased G-CSF levels significantly at 3, 6, and 24 h alone or in the presence of LPS (Fig. 8a). NRG-1 significantly increased IL-9 levels at 3 h following LPS stimulation (Fig. 8b). IL-9 was increased by all treatment conditions 6 and 24 h following NRG-1 and LPS administration.
Fig. 8

NRG-1 increases G-CSF and IL-9 concentrations in N9 microglia cells. N9 microglia cells were pre-treated with NRG-1 (100 ng/ml) for 24 h with or without LPS stimulation (10 μg/ml) for the indicated time points. Conditioned medium was collected and G-CSF (a) and IL-9 (b) levels were determined by Luminex. Results are expressed as the mean +/− SD. Asterisk denotes a significant difference compared to cells treated with only LPS (p < 0.05)

Discussion

NRG-1 has been shown to be neuroprotective and reduce inflammation in experimental models of ischemic stroke and neuroinflammation [1, 2, 3, 9, 10]; however, the molecular mechanism involved remains to be elucidated. Using CONFAC software, we were able to predict that the ability of NRG-1 to suppress ischemia-induced pro-inflammatory genes involved the modulation NF-kB pathways. NF-kB is known to be a master regulator of inflammation, which is the key contributor the pathology of ischemic stroke [24]. In post-mortem human brain samples of stroke patients, the NF-kB p65 subunit in particular has been found around the necrotic infarct core [22]. The NF-kB canonical pathway involves the phosphorylation and degradation of IkB leading to the nuclear translocation of p65/p50 NF-kB heterodimers to the nucleus where they stimulate the production of pro-inflammatory molecules [23, 24]. Using microglial cell cultures, we demonstrated that NRG-1 inhibited the LPS-induced phosphorylation and degradation of IkB-α, while also reducing the nuclear translocation of p65. This suggests that the mechanisms behind the anti-inflammatory/neuroprotective effects of NRG-1 involve the attenuation of the canonical NF-kB pathway.

The transcription factors identified by CONFAC did not change in mRNA expression in our analysis, including NF-kB family members. One of the primary reasons we chose a computational tool such as CONFAC is that it predicts transcription factors that change in activity, but not necessarily mRNA or protein levels. Indeed, induction of pro-inflammatory gene expression by NF-kB requires that cytoplasmic NF-kB p65/p50 translocates to the nucleus, but a change in NF-kB protein levels is not needed to mediate this effect. Over-representation of the NF-kB p65 TFBS indicates that it is more prevalent in the promoters of the genes in our dataset compared to a random set of genes. It does not indicate whether that promoter is activated or inhibited by the experimental paradigm. What our data suggest is that stroke causes transcriptional activation via the NF-kB p65-binding site, and NRG-1 prevents the binding of p65 to the TFBS by sequestering it in the cytoplasm.

The alternative NF-kB pathway is thought to have anti-inflammatory and anti-apoptotic roles [31, 35]. The alternative pathway activates NIK, a member of the MAP kinase family, which activates IKKα, resulting in the translocation of RelB/p52 NF-kB heterodimers to the nucleus. NIK-mediated activation of NF-kB is associated with the induction of anti-apoptotic and anti-inflammatory cytokines [30, 34, 37, 38, 50, 54, 55]. The alternative pathway is delayed relative to the canonical pathway, and only certain inducers are able to induce its activation [33]. In microglial cells, NRG-1 administration increased the nuclear levels of p52. In addition to dimerization with RelB, the p52 subunit is also able to homodimerize and considered to have a repressive role due to its lack of a transcription activation domain [32]. It has been previously shown that NRG-1 activates NIK [46]. These finding indicate that NRG-1 could both activate the alternative pathway and/or suppress NF-kB transcriptional activity via p52 [23, 32, 56].

Previous studies demonstrated that NRG-1 can activate the NF-kB signaling pathway cancer cells and Schwann cells [40, 41, 42, 43, 44, 45, 46]. In these studies, it appears that NRG-1 signals by activating NF-kB p65; however, the activation of NF-kB by NRG-1 in breast cancer cells is associated with the increased expression of anti-apoptotic genes. The discrepancy in the findings may be due to the differential expression of erbB receptors on the cells. In cancer cells and Schwann cells, NRG-1 signals through erbB2 and erbB3 receptors. Neuroprotection in stroke by NRG-1 is mediated by erbB4 which physically associates with NIK [46, 57]. Interestingly, NRG-1 alone has little effect on NF-kB in our in vitro studies. So, the anti-inflammatory effects of NRG-1 appear to be contextually related to the presence on a pro-inflammatory response.

Consistent with regulation of the alternative NF-kB pathway, NRG-1 induced the production of G-CSF and IL-9 in cell cultures. G-CSF has been shown to be neuroprotective in ischemic stroke models by inducing anti-apoptotic pathways, and IL-9 is known to promote cell proliferation and inhibit apoptosis [53, 58]. It has been reported that G-CSF significantly reduced the expression of microglial p65, reduced pro-inflammatory mediators, and promoted anti-inflammatory responses in models of multiple sclerosis [59, 60]. There are reports which suggest that IL-9 may have the ability to downregulate specific sets of genes induced by NF-kB by inducing the expression of BCL-3 [61]. BCL3 is an IkB protein that specifically associates with homodimers p50 and p52 and has been shown to regulate pro-survival genes. BCL3 is also able to repress transcription by increasing p52 homodimer binding to kB sites on DNA [62].

Conclusions

Stroke is a leading cause of death and disability in the USA. There is an urgent need to better understand the pathophysiology associated with stroke in order to develop more effective therapies. Here, we show that the neuroprotective and anti-inflammatory effects of NRG-1 are associated with the regulation of both canonical and alternative NF-kB signaling pathways. NRG-1 is currently in clinical trials for heart failure and has been shown to be safe and efficacious in phase I and phase II patient studies [63, 64]. These findings have major implications for the development of NRG-1 as a clinical therapy for stroke and other inflammation-mediated disorders.

Notes

Acknowledgements

We thank Timothy Distel for technical support.

Funding

This project was supported in part by NIH grants U54 NS060659 and U54 RR026137, G12RR003034, and S21MD000101.

Availability of data and materials

Raw data are available on personal demand.

Authors’ contributions

BF and LS conceived the study, participated in its design and coordination, and helped to draft the manuscript. MS, GF, and GN participated in its design and coordination of the study and helped to draft the manuscript. YL conducted the MCAO surgeries. LS and GN designed and performed the in vitro studies. LS, GF, and BF conducted the data analysis. All authors read and approved the final manuscript.

Competing interests

Patents related to the work being reported is held by the author (BF) without direct corporate involvement at the time.

Consent for publication

Not applicable

Ethics approval and consent to participate

The study protocol was approved by the Institutional Animal Care and Use Committee at Morehouse School of Medicine according to international guidelines prior to the initiation of experimentation.

References

  1. 1.
    Li Y, et al. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res. 2007;1184:277–83.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Xu Z, et al. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J Cereb Blood Flow Metab. 2006;26(4):527–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Xu Z, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19(3):461–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Iaci JF, et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke. Neuropharmacology. 2010;59(7-8):640–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Guo WP, et al. Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia. Brain Res. 2006;1087(1):180–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Shyu WC, et al. Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol Aging. 2004;25(7):935–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Xu Z, et al. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun. 2004;322(2):440–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Li Q, et al. Effect of neuregulin on apoptosis and expressions of STAT3 and GFAP in rats following cerebral ischemic reperfusion. J Mol Neurosci. 2009;37(1):67–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Solomon W, et al. Neuregulin-1 attenuates mortality associated with experimental cerebral malaria. J Neuroinflammation. 2014;11:9.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Li Y, et al. Neuregulin-1 inhibits neuroinflammatory responses in a rat model of organophosphate-nerve agent-induced delayed neuronal injury. J Neuroinflammation. 2015;12:64.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Dimayuga FO, et al. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol. 2003;136(1-2):67–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Touzani O, Roussel S, MacKenzie ET. The ischaemic penumbra. Curr Opin Neurol. 2001;14(1):83–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Rogove AD, Lu W, Tsirka SE. Microglial activation and recruitment, but not proliferation, suffice to mediate neurodegeneration. Cell Death Differ. 2002;9(8):801–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol. 2010;119(1):89–105.PubMedCrossRefGoogle Scholar
  16. 16.
    McKimmie CS, et al. Innate immune response gene expression profiles of N9 microglia are pathogen-type specific. J Neuroimmunol. 2006;175(1-2):128–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779–89.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Fernandes A, Miller-Fleming L, Pais TF. Microglia and inflammation: conspiracy, controversy or control? Cell Mol Life Sci. 2014;71(20):3969–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Graeber MB, Li W, Rodriguez ML. Role of microglia in CNS inflammation. FEBS Lett. 2011;585(23):3798–805.PubMedCrossRefGoogle Scholar
  20. 20.
    Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Widgerow AD. Cellular resolution of inflammation—catabasis. Wound Repair Regen. 2012;20(1):2–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Nurmi A, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke. 2004;35(4):987–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158(3):995–1006.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen CC, et al. Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes. J Biol Chem. 1998;273(31):19424–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Boulet I, et al. Lipopolysaccharide- and interferon-gamma-induced expression of hck and lyn tyrosine kinases in murine bone marrow-derived macrophages. Oncogene. 1992;7(4):703–10.PubMedGoogle Scholar
  27. 27.
    Ko HM, et al. Inflexin attenuates proinflammatory responses and nuclear factor-kappaB activation in LPS-treated microglia. Eur J Pharmacol. 2010;633(1-3):98–106.PubMedCrossRefGoogle Scholar
  28. 28.
    Jin H, et al. Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-kappaB signalling pathway activation. Phytother Res. 2012;26(9):1320–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang X, et al. Gomisin A inhibits lipopolysaccharide-induced inflammatory responses in N9 microglia via blocking the NF-kappaB/MAPKs pathway. Food Chem Toxicol. 2014;63:119–27.PubMedCrossRefGoogle Scholar
  30. 30.
    Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011;21(1):71–85.PubMedCrossRefGoogle Scholar
  31. 31.
    Lawrence T, et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005;434(7037):1138–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Xiao G, et al. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev. 2006;17(4):281–93.PubMedCrossRefGoogle Scholar
  34. 34.
    Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Marienfeld R, et al. RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem. 2003;278(22):19852–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Lwin T, et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin’s lymphoma cells. Leukemia. 2007;21(7):1521–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Zong WX, et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999;13(4):382–7.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Xia Y, et al. RelB regulation of chemokine expression modulates local inflammation. Am J Pathol. 1997;151(2):375–87.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Limpert AS, Carter BD. Axonal neuregulin 1 type III activates NF-kappaB in Schwann cells during myelin formation. J Biol Chem. 2010;285(22):16614–22.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Hinohara K, et al. ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A. 2012;109(17):6584–9.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Limpert AS, et al. NF-kappaB forms a complex with the chromatin remodeler BRG1 to regulate Schwann cell differentiation. J Neurosci. 2013;33(6):2388–97.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Frensing T, Kaltschmidt C, Schmitt-John T. Characterization of a neuregulin-1 gene promoter: positive regulation of type I isoforms by NF-kappaB. Biochim Biophys Acta. 2008;1779(2):139–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Han ME, et al. Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells. J Gastroenterol. 2015;50(6):645–56.PubMedCrossRefGoogle Scholar
  45. 45.
    Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 2002;21(13):2066–78.PubMedCrossRefGoogle Scholar
  46. 46.
    Chen D, et al. NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene. 2003;22(28):4348–55.PubMedCrossRefGoogle Scholar
  47. 47.
    Karanam S, Moreno CS. CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets. Nucleic Acids Res. 2004;32(Web Server issue):W475–84.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Pulliam JV, et al. Computational identification of conserved transcription factor binding sites upstream of genes induced in rat brain by transient focal ischemic stroke. Brain Res. 2013;1495:76–85.PubMedCrossRefGoogle Scholar
  49. 49.
    Ford G, et al. Expression Analysis Systematic Explorer (EASE) analysis reveals differential gene expression in permanent and transient focal stroke rat models. Brain Res. 2006;1071(1):226–36.PubMedCrossRefGoogle Scholar
  50. 50.
    Harari OA, Liao JK. NF-kappaB and innate immunity in ischemic stroke. Ann N Y Acad Sci. 2010;1207:32–40.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Acosta SA, et al. Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. PLoS One. 2014;9(3):e90953.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Shin YK, Cho SR. Exploring erythropoietin and G-CSF combination therapy in chronic stroke patients. Int J Mol Sci. 2016;17:4.CrossRefGoogle Scholar
  53. 53.
    Sikoglu EM, et al. Enhancement in cognitive function recovery by granulocyte-colony stimulating factor in a rodent model of traumatic brain injury. Behav Brain Res. 2014;259:354–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20(8):2687–95.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Yoza BK, et al. Induction of RelB participates in endotoxin tolerance. J Immunol. 2006;177(6):4080–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195–224.PubMedCrossRefGoogle Scholar
  57. 57.
    Guan YF, et al. Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission. Neuroscience. 2015;307:151–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Fontaine RH, et al. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Differ. 2008;15(10):1542–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Guo Y, et al. Granulocyte colony-stimulating factor improves alternative activation of microglia under microenvironment of spinal cord injury. Neuroscience. 2013;238:1–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Yamasaki R, et al. Restoration of microglial function by granulocyte-colony stimulating factor in ALS model mice. J Neuroimmunol. 2010;229(1-2):51–62.PubMedCrossRefGoogle Scholar
  61. 61.
    Richard M, et al. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood. 1999;93(12):4318–27.PubMedGoogle Scholar
  62. 62.
    Bundy DL, McKeithan TW. Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA. J Biol Chem. 1997;272(52):33132–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Gao R, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Jabbour A, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13(1):83–92.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Lauren J. Simmons
    • 1
  • Monique  C. Surles-Zeigler
    • 1
  • Yonggang Li
    • 2
  • Gregory D. Ford
    • 3
  • Gale D. Newman
    • 1
  • Byron D. Ford
    • 2
  1. 1.Morehouse School of MedicineAtlantaGeorgia
  2. 2.Division of Biomedical SciencesUniversity of California—Riverside School of MedicineRiversideUSA
  3. 3.Georgia Highlands CollegeCartersvilleUSA

Personalised recommendations